A retrospective study evaluated the effectiveness of immunotherapy in patients with EGFR-mutated NSCLC by assessing both PD-L1 expression and TME parameters, including numbers of CD8+ TILs [57]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.